In this study, we demonstrate that MCL cells that are resistant to bortezomib (Mino and Rec-1), showed lower levels of BACH2 than the bortezomib-sensitive MCL cells (Jeko and SP53). This evidence concerns the gene BACH2 and mantle cell lymphoma.